Anti-Amyloid Antibodies for Alzheimer’s Disease: Efficacy and Safety

This umbrella review evaluates the clinical efficacy and safety of two recently approved anti-amyloid antibodies, lecanemab and donanemab, for treating early-stage Alzheimer’s disease. By synthesizing data from eleven high-quality systematic reviews and meta-analyses, the authors conclude that these drugs successfully reduce brain amyloid burden and provide a statistically significant slowing of cognitive decline. However, the text highlights a critical concern: the observed cognitive benefits often fall below established clinically meaningful thresholds, suggesting that patients might not perceive a significant improvement in daily life. Furthermore, both treatments are associated with an increased risk of amyloid-related imaging abnormalities (ARIA), such as brain edema and hemorrhage, particularly in ApoEε4 gene carriers. Consequently, the source emphasizes that prescribing these therapies requires rigorous patient selection, careful monitoring through regular MRIs, and transparent communication regarding the modest expected outcomes. Ultimately, while these antibodies represent a significant pharmacological shift in dementia care, their benefits must be carefully weighed against potential safety risks and high financial costs.